Myrexis (Myrexis) Growth Rank : 0 (As of May. 01, 2024)

View and export this data going back to 2013. Start your Free Trial

What is Myrexis Growth Rank?

Myrexis has the Growth Rank of 0.

GuruFocus Growth Rank measures the growth of a company in terms of its revenue and profitability. Historically, the companies with the highest growth ranks performed the best over the long term. It is calculated using the following criteria:

1. 5-year revenue growth rate, the higher, the better.
2. 3-year revenue growth rate, the higher, the better.
3. 5-year EBITDA growth rate, the higher, the better.
4. The predictability of 5-year revenue. The most consistent it is, the higher the rank.

GuruFocus found that the Growth Rank is the second of the two most-sensitive parameters among the five parameters checked. Please click GF Score to see more details on GF Score's 5 Key Aspects of Analysis.

Please note that we are using the five-year EBITDA growth rate as a parameter, so the company needs to have had positive growth over that time. The reason we use EBITDA instead of earnings per share is that with EBITDA, we can rank a lot more companies since a company may have positive EBITDA but negative EPS. Since we are looking at the growth here, EBITDA gives us a pretty clear picture about the growth in the company's business operations.

Myrexis Growth Rank Related Terms

Thank you for viewing the detailed overview of Myrexis's Growth Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Myrexis (Myrexis) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Financial Services » Diversified Financial Services » Myrexis Inc (OTCPK:MYRX) » Definitions » Growth Rank

Comparable Companies

Traded in Other Exchanges

N/A

Address

630 Fifth Avenue, Suite 2260, New York, NY, USA, 10020

Website

http://www.myrexis.com

Myrexis Inc is engaged in evaluating strategic alternatives, such as identifying, evaluating and making financial investments in life sciences assets.

Executives

Xstelos Corp.	10 percent owner	630 FIFTH AVENUE, SUITE 2260, NEW YORK NY 10020
Steven D Scheiwe	director	1741 EDGEFIELD LANE, ENCINITAS CA 92024
Pearce Michael Cooper	director	213 RHODODENDRON DRIVE, CHAPEL HILL NC 27517
Jonathan Couchman	director, officer: Chairman, President and CEO	630 FIFTH AVENUE, SUITE 2260, NEW YORK NY 10020
John T Henderson	director	320 WAKARA WAY, SALT LAKE CITY UT 84108
First Eagle Investment Management, Llc	10 percent owner	1345 AVENUE OF THE AMERICAS, NEW YORK NY 10105
Jason Aryeh	director	11119 NORTH TORREY PINES ROAD, SUITE 200, LA JOLLA CA 92037
Gerald P. Belle	director	320 WAKARA WAY, SALT LAKE CITY UT 84108
David W Gryska	director, officer: Chief Operating Officer	749 N MARY AVE, SUNNYVALE CA 94085
Richard B Brewer	director, officer: President and CEO	C/O DENDREON CORP, 3005 1ST AVE, SEATTLE WA 98121
Timothy R Franson	director	320 WAKARA WAY, SALT LAKE CITY UT 84108
Dennis Langer	director	C/O PETER TSOFLIAS, BLANK ROME LLP, ONE LOGAN SQUARE, FL 9, PHILADELPHA PA 19103
Robert Forrester	director	C/O COMBINATORX, INCORPORATED, 245 FIRST STREET, 3RD FLOOR, CAMBRIDGE MA 02142
Adrian N Hobden	director, officer: President and CEO	320 WAKARA WAY, SALT LAKE CITY UT 84108
W Wayne Laslie	officer: Chief Operating Officer	320 WAKARA WAY, SALT LAKE CITY UT 84108

Myrexis (Myrexis) Headlines

From GuruFocus

Myriad Pharmaceuticals Inc. Reports Operating Results (10-Q)

By gurufocus 10qk • 02-09-2011

Myriad Pharmaceuticals Inc. Reports Operating Results (10-Q)

By gurufocus 10qk • 02-16-2010

Myriad Pharmaceuticals Inc. Reports Operating Results (10-Q)

By gurufocus 10qk • 11-12-2009

Myriad Pharmaceuticals Inc. Reports Operating Results (10-Q)

By gurufocus 10qk • 05-17-2010

Myriad Pharmaceuticals Inc. Reports Operating Results (10-K)

By gurufocus 10qk • 09-13-2010